Weekly Digest – November 2025 Weekly Digest – November 2025 25 November 2025: U.S. FDA approves PADCEV plus Keytruda for certain patients with bladder cancer The FDA has approved PADCEV (enfortumab vedotin-ejfv) plus Keytruda as the first perioperative regimen to […]
Weekly Digest – November 2025 Weekly Digest – November 2025 24 November 2025: Blenrep approved in Australia for use in adults with relapsed or refractory multiple myeloma as part of triplet combination therapy Australia has approved Blenrep (belantamab mafodotin), a first-of-its-kind […]
Weekly Digest – November 2025 Weekly Digest – November 2025 24 November 2025: Sichuan Biokin Pharmaceutical announces acceptance of the New Drug Application for Iza-Bren (an EGFR×HER3 Bispecific ADC) for the treatment of locally advanced or metastatic nasopharyngeal carcinoma China’s […]
Weekly Digest – November 2025 Weekly Digest – November 2025 24 November 2025: Avenzo Therapeutics granted Fast Track Designation for AVZO-103, a potential best-in-class nectin4/TROP2 bispecific ADC, for the treatment of patients with urothelial cancer previously treated with enfortumab vedotin […]
Weekly Digest – November 2025 Weekly Digest – November 2025 27 November 2025: IntoCell receives FDA IND approval for advanced solid tumor treatment ‘ITC-6146RO’ IntoCell received FDA IND approval for ITC-6146RO, a B7-H3 targeting antibody-drug conjugate for advanced solid tumors, […]
Weekly Digest – November 2025 Weekly Digest – November 2025 27 November 2025: Aptis and Cobx Bio partner to develop DAC cancer drugs Aptis (a Dong-A ST subsidiary) and Cobx Bio have signed a collaboration agreement to jointly develop a […]
